Adjuvant chemotherapy in advanced stage epithelial ovarian cancer

Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados

Objective: to describe the efficacy of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer in Hospital de San José, Bogotá, Colombia, between 2016 and 2020. Materials and methods: a descriptive historical cohort study in patients with epithelial ovarian cancer managed with complete surgical cytoreduction followed by 6 carboplatin-paclitaxel chemotherapy cycles. The follow-up time was approximately 1 year. Results: out of the 45 studied patients managed with optimal cytoreduction followed by adjuvant chemotherapy, cancer progression was observed in 13/45 (29%) cases, 2/45 (4%) showed partial response and 30/45 (66.6%) showed complete response. Chemotherapy-related adverse effects occurred in (n = 45/45, 100%), including alopecia (n = 45/45, 100%), nausea and vomiting (n = 30/45, 67%), arthralgia (n = 10/45, 22%), peripheral neuropathy reported as hands and feet paresthesia (n = 6/45, 13%) and one case (2%) had grade I hematologic toxicity (mild neutropenia). Conclusions: 66.6% of patients with epithelial ovarian cancer treated with optimal cytoreduction and adjuvant chemotherapy exhibited complete response to chemotherapy with better tolerance to chemotherapy (carboplatin-paclitaxel) related adverse effects.

1. International Agency for Research on Cancer. Global Cancer Observatory [Internet]. World Health Organization; 2021 [Consultado 2021]. Available from: https://gco.iarc.fr/
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. https://doi.org/10.3322/caac.21254
3. Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy Resistance in Advanced Ovarian Cancer Patients. Biomark Cancer. 2019;11:1179299X1986081. https://doi.org/10.1177/1179299X19860815.
4. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. http://dx.doi.org/10.1016/j.bpobgyn.2016.08.006
5. Lei Z, Wang Y, Wang J, Wang K, Tian J, Zhao Y, et al. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer. JAMA Netw open. 2020;3(8):e2013940. doi: 10.1001/jamanetworkopen.2020.13940
6. Monk BJ, Randall LM, Grisham RN. The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer. Am Soc Clin Oncol Educ B. 2019;39:e141–51. doi: 10.1200/EDBK_239007
7. Trimbos JB. Surgical treatment of early-stage ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41(2017):60–70. http://dx.doi.org/10.1016/j.bpobgyn.2016.10.001
8. Bois A Du, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234–44. https://doi.org/10.1002/cncr.24149.
9. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am. 2018;32(6):943–64. https://doi.org/10.1016/j.hoc.2018.07.010
10. Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Front Immunol. 2020;11: 577869. doi: 10.3389/fimmu.2020.577869
11. Broekman KE, van Kruchten M, van Tinteren H, Sessa C, Jalving M, Reyners AKL. Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores. ESMO Open. 2021;6(4):100229. https://doi.org/10.1016/j.esmoop.2021.100229
12. Isabelle RC, Isabelle TF, Eric PL, Liu JF, Selle F, Poveda AM, et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patientswith advanced platinum-resistant or -refractory ovarian cancer. J Clin Oncol. 2016;34(36):4345–53. doi: 10.1200/JCO.2016.67.1891
13. Murphy M, Martin G, Mahmoudjafari Z, Bivona C, Grauer D, Henry D. Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer. J Oncol Pharm Pract. 2020;26(7):1566–74. https://doi.org/10.1177/1078155219899460
14. Du Bois A, Lück HJ, Meier W et al. No TitCarboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.le. Semin Onco. 1997;24(5):s15–52.
15. Coleman RL, Hennessy BT, Coleman RL, Markman M. Fallopian, Including Cancer, Tube Cancer, Primary Peritoneal. NCCN. 2021;1.
16. Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Control Release. 2016;243:250–68. http://dx.doi.org/10.1016/j.jconrel.2016.10.014
17. Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–505. doi: 10.1056/NEJMoa1810858
18. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200. https://doi.org/10.1200/JCO.2003.02.153.
19. Huang CY, Cheng M, Lee NR, Huang HY, Lee WL, Chang WH, et al. Comparing paclitaxel-"carboplatin with paclitaxel-"cisplatin as the front-line chemotherapy for patients with FIGO IIIC serous-type tubo-ovarian cancer. Int J Environ Res Public Health. 2020;17(7):2213. https://doi.org/10.3390/ijerph17072213.